AstraZeneca's Crestor approved in US for paediatric use; Vimovo filed in Europe

AstraZeneca announced that the FDA approved Crestor (rosuvastatin) for use in children aged 10 years to 17 years with heterozygous familial hypercholesterolaemia. The company noted it would not “actively promote this indication.”

Separately, the company reported that along with its partner Pozen, a regulatory filing was made in Europe for Vimovo (naproxen/immediate release esomeprazole), as a treatment for the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who are at risk of developing NSAID-associated ulcers.

In June, Pozen submitted a US regulatory application for the drug.

To read more Top Story articles, click here.